In line with the hypothesis that IGF may be important in bone and lymph node metastases, patients with non-visceral involvement were identified as a subgroup with potential benefit from treatment with Xe1000+Ev10+Ex25 versus Ev10+Ex25 (HR 0.21 [95% CI 0.05–0.98]). This evidence concerns the gene IGF1 and metastatic malignant neoplasm in the lymph nodes.